Insider Buying: Diaceutics (LON:DXRX) Insider Buys 91 Shares of Stock

Key Points

• Insider Nick Roberts purchased 91 shares of Diaceutics PLC (LON:DXRX) at an average price of GBX 165 per share on October 1st.
• Diaceutics reports a negative earnings per share (EPS) of GBX (2.84) and a negative net margin of 10.90% for the last quarter.
• Analysts maintain a generally positive outlook, with a current average target price of GBX 175 and multiple upgrades, despite recent price downgrades.

Diaceutics PLC (LON:DXRX - Get Free Report) insider Nick Roberts purchased 91 shares of the business's stock in a transaction dated Wednesday, October 1st. The shares were acquired at an average cost of GBX 165 per share, for a total transaction of £150.15.

Diaceutics Stock Performance

Diaceutics stock opened at GBX 165 on Thursday. The firm has a market capitalization of £139.50 million, a price-to-earnings ratio of -8,168.32 and a beta of 0.58. Diaceutics PLC has a 52 week low of GBX 106 and a 52 week high of GBX 167. The company has a debt-to-equity ratio of 0.39, a quick ratio of 9.92 and a current ratio of 4.85. The company has a 50 day moving average price of GBX 142.58 and a 200 day moving average price of GBX 129.32.

Diaceutics (LON:DXRX - Get Free Report) last announced its earnings results on Tuesday, September 23rd. The company reported GBX (2.84) earnings per share (EPS) for the quarter. Diaceutics had a negative return on equity of 7.15% and a negative net margin of 10.90%. Research analysts forecast that Diaceutics PLC will post 1.0107919 EPS for the current year.

Analyst Upgrades and Downgrades

A number of research analysts recently issued reports on the company. Royal Bank Of Canada decreased their price objective on Diaceutics from GBX 195 to GBX 185 and set an "outperform" rating for the company in a report on Thursday, July 10th. Canaccord Genuity Group restated a "buy" rating and issued a GBX 180 price target on shares of Diaceutics in a research note on Tuesday, July 22nd. Three analysts have rated the stock with a Buy rating, Based on data from MarketBeat, the company presently has an average rating of "Buy" and an average target price of GBX 175.

About Diaceutics

At Diaceutics we believe that every patient should get the opportunity to receive the right test and the right therapy to positively impact their disease outcome. We provide the world's leading pharma and biotech companies with an end-to-end commercialisation solution for precision medicines through data analytics, scientific and advisory services enabled by our platform DXRX - The Diagnostics Network®.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.